论文部分内容阅读
目的对比观察化疗、放疗与放化疗同步治疗Ⅲ期非小细胞肺癌(NSCLC)的疗效以及并发症。方法将省肿瘤医院放疗科68例Ⅲ期NSCLC患者随机分为放化疗同步组(A组)和单纯放疗组(B组)与同期邹城市中医院肿瘤科单纯化疗组(C组)35例进行疗效比较。放疗采用累及野三维适形调强照射,2.0Gy/次,1次/d,5d/周。总DT(66-68)Gy/(6.6-7.0)周。化疗方案为鳞癌给予EP方案,腺癌给予MVP方案,腺鳞癌给予NP方案。结果总有效率A组为76.5%,B组为52.9%,C组为54.3%。A组优于B组、C组,AB、AC组间差异有统计学意义(P<0.05);1、2、3年生存率A组分别为70.6%、50.1%、35.3%,B组为52.9%、26.5%、14.7%,C组为54.3%、25.7%、11.4%,A组优于B组、C组,AB、AC组间差异有统计学意义(P<0.05);三组毒副反应表现为放化疗不良反应,均能耐受。结论放化疗同步治疗晚期NSCLC可提高有效率,减少远处转移率,从而提高远期生存率。
Objective To compare the curative effect and complications of concurrent chemotherapy, radiotherapy and radiotherapy and chemotherapy for stage Ⅲ non-small cell lung cancer (NSCLC). Methods Sixty-eight patients with stage Ⅲ NSCLC undergoing radiotherapy and chemotherapy in Provincial Cancer Hospital were randomly divided into radiotherapy and chemotherapy group (group A) and radiotherapy group (group B) with 35 patients in the chemotherapy group (group C) of oncology department of Zoucheng Hospital of Traditional Chinese Medicine Comparison of efficacy. Radiotherapy Involved with wild three-dimensional conformal IMRT, 2.0 Gy / time, 1 time / d, 5d / week. Total DT (66-68) Gy / (6.6-7.0) weeks. Chemotherapy for squamous cell carcinoma given EP program, adenocarcinoma given MVP program, adenosquamous carcinoma given NP program. Results The total effective rate was 76.5% in group A, 52.9% in group B and 54.3% in group C. The difference between group A and group B was statistically significant (P <0.05), and the one, two and three year survival rates were 70.6%, 50.1% and 35.3% respectively in group A and group B 52.9%, 26.5% and 14.7% in group C, 54.3%, 25.7% and 11.4% in group C respectively. The difference between group A and group B was statistically significant (P <0.05) Side effects of radiotherapy and chemotherapy adverse reactions, can tolerate. Conclusions The concurrent treatment of advanced NSCLC with radiotherapy and chemotherapy can improve the efficiency, reduce the distant metastasis rate and improve the long-term survival rate.